Abstract
A phase II trial was conducted to evaluate the efficacy and toxicity of the Egorin's carboplatin dosing formula with 14-day oral etoposide in 38 elderly patients with small-cell lung cancer (SCLC). The overall response rate was 81%. Median survival times were 15.1 months for 16 limited-disease (LD) and 8.6 months for 22 extensive-disease (ED) patients. Myelosuppression was the principal side-effect. This regimen is an active regimen in the treatment of elderly SCLC patients.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carboplatin / administration & dosage*
-
Carboplatin / adverse effects
-
Carcinoma, Small Cell / drug therapy*
-
Carcinoma, Small Cell / mortality
-
Etoposide / administration & dosage*
-
Etoposide / adverse effects
-
Female
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / mortality
-
Male